On May 31, 2023 Alpha Cancer Technologies Inc. (ACT), a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, reported details from the company’s abstract published as part of the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Alpha Cancer Technologies, MAY 31, 2023, View Source [SID1234632311]). The ASCO (Free ASCO Whitepaper) meeting will take place in Chicago from June 2-6, 2023.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"ACT continues to build upon the body of evidence supporting our novel approach of targeting alpha fetoprotein receptors for the treatment of cancer using our truly next-generation ADC technology," said Dr. Igor Sherman, CEO of ACT. "By selectively targeting cancer cells and myeloid derived suppressor cells we can deliver toxins directly to the tumor, leading to enhanced therapeutic efficacy while mitigating many of the side effects associated with traditional ADC treatments. Now across multiple tumor models, we have observed high activity in treatment groups including statistically significant dose-dependent reduction in tumor volume and increased survival. With robust preclinical data demonstrating both safety and efficacy, we look forward to taking ACT-903 into the clinic next year."
The abstract, entitled "Efficacy and safety study of a novel Alpha-fetoprotein (AFP)-Maytansine conjugate in an ovarian xenograft model" was selected by the ASCO (Free ASCO Whitepaper) Scientific Program Committee for publication in the 2023 ASCO (Free ASCO Whitepaper) Annual Meeting Proceedings, a supplement to the Journal of Clinical Oncology. The research used an ovarian xenograft model compared to control with four dosing regimens of the AFP-maytansine conjugate, ACT-903. Tumor growth, survival, and clinical observations were assessed 62 days following implantation. Separately, organoids were cultured from primary reprogrammed tumor cells from two different patients with high-grade serous ovarian carcinoma and treated with ACT-903 to observe cytotoxicity.
The results in the ovarian xenograft models, consistent with prior research conducted by ACT using colorectal xenograft models, show a statistically significant dose-dependent reduction in tumor volume (p<0.001) and increase in survival (p<0.002) in all treatment groups when compared to the control group. All mice survived to the end of the study (day 62) in Groups 1, 3, and 4, and 6 out of 10 mice survived in the lowest dose group. In the control group, all animals were dead by day 38 due to excessive tumor burden. In the highest dose group, 100% of the mice had complete tumor regression with no regrowth at the end of the study. No signs of toxicity were observed in any treatment group. In the two ovarian organoids, ACT-903 demonstrated a cytotoxic effect over 72 hours similar to that of other known anti-cancer agents, such as paclitaxel and cisplatin.
The results from this study demonstrating the safety and efficacy of ACT-903 in ovarian xenograft models and the cytotoxicity observed in patient-derived cancer organoids support advancement of ACT-903 into clinical studies. ACT plans to submit an Investigational New Drug (IND) application for ACT-903 in 2024.